Investors are beginning to turn cautious on biotechnology stocks as a rapid rise in Treasury yields dents the appeal for shares of companies that are often viewed as risky all-or-nothing bets on breakthrough medical treatments.
The health-care corner of the US equity market has traditionally been viewed as defensive, thanks to steady growth and healthy dividend yields among the industry’s stalwarts. That narrative is changing.
